THE ARISING · EDITED READER EDITION
The Arising · November 17 Edited Reader Edition
This edited reader edition includes 16 reviewed articles from November 17, 2026. It is not the complete original issue. It includes 16 of the original 34 stories; 18 are not included here.
Longevity & Healthspan
VITAL found fewer heart attacks with fish oil, but its main outcome did not improve
November 17, 2026 · Longevity & Healthspan · By The Arising Longevity & Healthspan Desk
A new review by the VITAL investigators revisits a result that is easy to oversimplify. In their original randomized trial, a daily fish-oil capsule did not significantly reduce the combined outcome of heart attack, stroke or cardiovascular death. Heart attacks considered separately were less common, but that was a secondary result.
The trial assigned 25,871 U.S. adults to fish oil or placebo and followed them for a median of 5.3 years. There were 304 major cardiovascular events in the fish-oil group and 333 in the placebo group; the hazard ratio was 0.92 (95% confidence interval 0.80–1.06). For heart attacks alone, the counts were 145 and 200, respectively, with a hazard ratio of 0.72 (0.59–0.90).
Those two findings can coexist. The heart-attack result concerns one outcome among several, and it does not overturn the uncertainty around the trial's primary cardiovascular outcome. The 2026 overview draws on the same VITAL trial, not a new randomized replication. It does not establish a general reason to start taking fish oil.
Longevity & Healthspan
Higher total sugar intake tracked with cognitive risk, but the evidence is uncertain
November 17, 2026 | The Arising
Is sugar itself driving cognitive decline, or is it a clue to a broader pattern of diet and health? A new review finds a signal, but it cannot tell those explanations apart.
In five prospective cohorts with 200,812 participants, researchers compared people reporting the highest and lowest amounts of total dietary sugar. The highest-intake groups had a 23% higher relative rate of cognitive disorders during follow-up (hazard ratio 1.23; 95% confidence interval 1.10–1.38). The authors rated this evidence low certainty. That is a relative comparison between groups, not a 23-point rise in anyone's chance of developing dementia. The review included several cognitive outcomes, so the number is not specific to Alzheimer's disease.
Other pooled comparisons, including sugar-sweetened beverages and several individual sugars, did not show statistically clear associations. Some estimates were imprecise. That does not establish that all sugar sources have the same effects, or that the foods and amounts within the highest and lowest groups were comparable across studies.
The reasonable takeaway is that a signal warrants more study. Participants reported their diets, health and lifestyle differences may still have influenced the results, and the studies did not assign people to change what they ate. The review doesn't show that eating less sugar prevents dementia or identify a cutoff that would do so.
Source: Dietary Sugar Intake and Risk of Cognitive Disorders, Nutrition Reviews.
Longevity & Healthspan
A bone-remodeling marker rose after high-intensity training
November 17, 2026 · Longevity & Healthspan · By The Arising Longevity & Healthspan Desk
Changing a blood marker and strengthening a bone are different outcomes. A systematic review of 24 randomized trials with 1,238 healthy adults found an increase in osteocalcin after high-intensity exercise compared with no training. Osteocalcin is involved in bone remodeling, the ongoing replacement of old bone tissue.
The review did not detect a clear osteocalcin change in its separate analyses of endurance or power training. That is not proof those exercises do nothing for bone, or that one exercise type outperformed another in a direct comparison. Training programs differed, and the high-intensity finding drew on impact-based interval exercise; the authors did not establish that non-impact intervals would produce the same response.
The main result is about a laboratory measurement. The review does not show that the marker increase led to stronger bones or fewer fractures. Those outcomes need evidence that measures them directly.
Longevity & Healthspan
AI drafts shortened heart ultrasound review in one trial, but half needed substantial edits
November 17, 2026 · Longevity & Healthspan · By The Arising Longevity & Healthspan Desk
What changes if a cardiologist starts with a draft written by AI? In a randomized study presented at the American Heart Association’s Scientific Sessions, the average time to review and finalize a heart ultrasound report fell from 8.5 minutes with a human draft to 4.6 minutes with an AI draft.
The study used 1,200 echocardiograms from 21 Kaiser Permanente Northern California medical centers. Cardiologists were randomly assigned drafts to finalize without being told who or what wrote them. They made substantial changes to 50.6% of AI drafts and 49.7% of human drafts. That met the study's noninferiority criterion on the edit-rate measure. It did not show that the unreviewed drafts were diagnostically equivalent or safe to use on their own.
The shorter review time tells us about the reporting task in one health system. It does not tell us whether patients received results faster or whether their care improved. The findings were reported at a conference and should be treated as preliminary.
Conference organizer’s study summary: AHA Late-Breaking Science Abstract 28202
Longevity & Healthspan
Experimental retatrutide reduced sleep apnea events in two trials
November 17, 2026 · Longevity & Healthspan · By The Arising Longevity & Healthspan Desk
Two late-stage randomized trials found that retatrutide, an investigational weekly injection, reduced breathing interruptions during sleep more than placebo. The Lilly-funded trials enrolled 691 adults with moderate-to-severe obstructive sleep apnea and a body-mass index of at least 27. One trial enrolled adults without type 2 diabetes; the other enrolled adults with it.
After 80 weeks, the two higher-dose study groups without diabetes had about 22 to 24 fewer breathing events per hour than placebo. In the trial with diabetes, the difference was about 14 to 15 per hour. These numbers compare changes between randomized groups; they are not the number of events participants still had at the end. A separate analysis by original treatment assignment produced similar estimates.
Participants on retatrutide also lost more weight. The most common side effects involved the digestive system. The trials compared the drug with placebo, not with a positive airway pressure device, and they did not establish that patients could stop their existing treatment. Retatrutide remains investigational and is not FDA-approved.
Primary source: TRIUMPH-1-OSA and TRIUMPH-2-OSA in NEJM · Investigational status
Longevity & Healthspan
Long COVID trial found a symptom signal, but did not use a sham device
November 17, 2026 · Longevity & Healthspan
A randomized trial tested whether a device that stimulates the vagus nerve through the skin, a structured sound program, or both could change symptoms in adults with long COVID. The Neuromodulation study was published October 8 and drew renewed attention after a November company announcement.
The four-week study compared the three interventions with monitoring alone. The journal report treated overall long COVID symptom burden as the primary outcome and a self-reported depressive symptom score as secondary. Depressive symptom scores improved in the active groups, but that secondary signal should not be read as proof that either intervention treats long COVID or depression.
Participants knew whether they were receiving an intervention, and the comparison group used no sham device or matching sound program. That makes it difficult to distinguish a specific treatment effect from expectations or extra attention. The published analysis also included only 250 of 541 people re-enrolled after a protocol change. It required completed outcomes and, in active groups, at least half of the scheduled use. Restricting the comparison after randomization can make the remaining groups less comparable.
The registry lists a slightly different enrollment total (546) and includes depression among its primary measures; the report uses the post-amendment enrollment and names depression as secondary. These records describe the study differently. A larger, blinded comparison with a credible sham and analysis that retains participants as randomized would be more informative. The lead investigator is a co-founder and executive of the device maker, and a co-author founded the company behind the sound program.
Longevity & Healthspan
Repeat smartwatch ECGs reduced false alarms in a preliminary study, but missed more cases
November 17, 2026 · Longevity & Healthspan · By The Arising Longevity & Healthspan Desk
An AI model tested on smartwatch ECGs sometimes reached different conclusions about the same person. In a preliminary South Korean study, 2,211 adults scheduled for heart ultrasound recorded ECGs with an Apple Watch and a Samsung Galaxy Watch during the same clinic visit. With the same cutoff applied to both devices, the model classified 200 people differently, about 9%.
A separate home-monitoring group showed the trade-off of requiring repeated positive results. Among 108 participants who recorded on at least five days, requiring positive results on two of three consecutive days cut false positives from 18 to nine among the 70 people without reduced pumping function. It also detected 31 of 38 cases rather than 33 on the single-positive-day rule.
Fewer false alarms came at the cost of missing two more cases. The home analysis was small, most participants used one watch brand, and the results were presented at a conference. A watch ECG records electrical activity; it does not directly measure how well the heart pumps. This study does not establish a consumer screening or diagnostic rule.
Conference organizer’s study summary: AHA Late-Breaking Science Abstract 27869
Longevity & Healthspan
Lifting speed may shape which benefits older adults see from strength training
November 17, 2026 · Longevity & Healthspan · By The Arising Longevity & Healthspan Desk
A review of resistance training in adults aged 60 and older found improvements in muscle strength and performance on physical tasks compared with no training. It included 16 eligible studies with 801 participants, with data available from 15 randomized trials.
Programs that asked participants to try to lift quickly showed larger gains on tests of physical function in subgroup analyses. Programs using deliberately slower lifts showed larger gains in muscle size and strength. Here, “quickly” describes the intended speed of the lifting phase in the studies, not a call to rush through a workout.
The comparisons combined studies with different loads, schedules and participants. They do not establish that any one lifting speed is best for everyone, or that a better score on a chair-rise or walking test necessarily translates into fewer falls or longer independence. The broader finding was that resistance training helped across multiple measured outcomes, while speed may be one factor in what improves.
Primary source: Tao and colleagues’ 2026 systematic review and meta-analysis
Longevity & Healthspan
A postbiotic changed blood markers, not overall menopause symptoms
November 17, 2026 | The Arising
The goal of a menopause supplement is to make people feel better. A 12-week Japanese trial of a heat-killed bacterial preparation shows why that is a different test from changing a blood marker.
The double-blind trial enrolled 121 women, and 119 completed it. Overall, the preparation did not outperform placebo on questionnaires about mood, menopause symptoms or sleep. Two blood markers, soluble CD14 and lactate dehydrogenase, shifted differently between the groups. Neither directly measures whether a person feels better, and neither establishes that the supplement repaired the gut barrier.
A prespecified subgroup of women with worse mood at baseline showed possible improvements in hot flashes and staying asleep. Those differences did not hold up in a second analysis adjusting for baseline measures. That makes the subgroup a question for another trial, not a reason to promote the supplement for hot flashes or insomnia. The results concern one heat-killed bacterial preparation, not all postbiotics or probiotics.
Source: Randomized, double-blind, placebo-controlled trial, Nutrients.
Measurement & AI
What should a personal AI agent be allowed to do with health paperwork?
November 17, 2026 · Measurement & AI · Commentary
A personal assistant could help track a missed reimbursement or organize questions for a clinic. Its job changes when it starts sending your medical information or changing an appointment. At that point, the more important question is not how little you notice the assistant. It is how clearly you can see what it is about to do.
In a September episode of the a16z Show, investor Anish Acharya and Assistant Benchmark creator David Pawlan discussed a future in which assistants handle routine tasks without waiting for a fresh instruction. That's a prediction about a market, not a study of how healthcare works. Pawlan's project publishes its test dimensions, scores and examples of runs. The creator's scoring can help people understand what was tested, but it does not independently demonstrate that these tools reduce healthcare paperwork, improve access to care, or make fewer mistakes.
Consider a delayed insurance reimbursement. An assistant could start with a checklist: identify the documents required, note the deadline and draft a message. It can do that without submitting a claim or deciding what to disclose. Before sending, a person should be able to check the recipient, the attachments, what is being requested and any deadline or financial commitment. The assistant should also make it easy to see afterward what was actually sent.
Medical information needs particular care. The U.S. Department of Health and Human Services explains that information a person enters into a consumer app generally isn't covered by HIPAA unless the app is provided by a covered entity or its business associate. The fact that the same information originally came from a medical record does not automatically extend those protections to the app. Before sharing it, check who receives it, how it is used and whether it can be removed.
A useful test is whether an assistant saves time without making someone less able to catch a mistake. Start with a task that doesn't change care or disclose records. Keep a person in control of anything that sends sensitive information, commits money or changes an appointment or treatment. Quiet help is welcome; the decision to act should still be visible.
Original a16z discussion · Assistant Benchmark methods and dimensions · HHS guidance on consumer apps and health information
Longevity & Healthspan
What’s changing in women’s preventive care? For now, the review process.
A new federal funding opportunity could help update the guidelines. It does not change what is recommended or covered today.
A preventive service only helps if people know about it and can get it. A new federal funding opportunity takes aim at both problems: keeping women’s preventive care recommendations current and helping clinics put them into practice.
On November 6, the U.S. Department of Health and Human Services and the Health Resources and Services Administration announced the Women’s Initiative for Screening and Health. The opportunity would provide up to $1 million in fiscal year 2027 to one organization. HRSA’s listing gives January 8, 2027 as the application deadline.
The organization would bring together at least ten experts and representatives from clinical, public health, patient and community organizations. The group would review scientific evidence and could recommend either updates or reaffirming existing guidance. It would also help get the recommendations into clinics and communities, including places where access to preventive care is limited.
Why does a review matter? Non-grandfathered group plans and individual health coverage generally must cover HRSA-supported preventive services without deductibles, coinsurance or copays. But there is a difference between a grant announcement, a committee’s recommendation, and official guidance that applies to coverage.
This announcement is the first of those steps. It is not evidence that a new screening test works, confirmation that a particular organization received an award, or a change to anyone’s benefits today. The practical thing to follow is what HRSA publishes as official guidance, and when it takes effect.
Sources
Longevity & Healthspan
A blood marker tracks slower walking. That doesn’t make it a screening test.
A review of 21 studies links a fragment from the nerve-muscle junction with poorer physical performance.
Walking speed is easy to observe. The harder question is what changes in the body when it begins to slow. One candidate is C-terminal agrin fragment, or CAF22, a circulating fragment researchers study in connection with the junction where nerves signal muscles.
A systematic review and meta-analysis examined 21 studies of aging and chronic disease populations. The walking-speed analysis included 33 cohorts with 3,136 participants. The analysis of the Short Physical Performance Battery, which uses several brief movement tests, drew on 28 cohorts with 2,773 participants. Those groups can overlap, so the counts should not be added together.
Higher CAF22 concentrations were associated with slower walking, with a pooled correlation of −0.31 (95% confidence interval, −0.35 to −0.27). The correlation with the broader physical performance score was −0.35 (95% confidence interval, −0.40 to −0.31). People with higher values generally did worse on those measures, but the relationships were far from exact.
That makes CAF22 interesting for research, not ready for screening. The pooled correlations do not tell us what cutoff would identify an individual whose mobility will decline later, or whether a blood test adds useful information beyond the physical tests themselves.
The test worth doing next is prospective: does measuring CAF22 change what clinicians can predict or do, beyond watching how someone walks, stands and moves? An association with function is a place to start, not a substitute for measuring function.
Source
Longevity & Healthspan
More tracker users meet exercise guidelines. The tracker may not be why.
A U.S. survey points to a gap in activity and access, but it cannot tell us what happens when someone gets a wearable.
People who track their activity often look more active in surveys. The harder question is whether the tracker changed their habits, or whether people who already exercise are more likely to use one. A new analysis helps describe the first pattern without answering the second question.
Researchers used the National Cancer Institute’s 2024 Health Information National Trends Survey. The survey had 7,278 respondents. The researchers identified patterns of digital health use in 5,804 people with complete data for that step; 4,930 had the information needed for the main regression analysis.
In that group, a weighted 31.4% of adults in the wearable-centered group reported meeting both aerobic and muscle-strengthening guidelines, compared with 18.2% in the limited-engagement group. The figures were 32.7% for people who used a broader mix of digital health tools and 19.9% for people whose engagement centered on patient portals. The wearable-centered association with meeting both guidelines remained after adjustment for measured differences.
These are survey estimates based on self-reported activity, not readings downloaded from trackers. The study took a snapshot in time, and the people excluded for missing data tended to be older and less economically advantaged. Differences in motivation, access or health could help explain the result.
A tracker can give someone feedback if it fits the way they already move. This study gives no reason to make one a prerequisite. It also asks a useful design question: how do we support walking and strength training for people who don’t want to, or can’t, use a device?
Source
Longevity & Healthspan
An investigational drug reduced low blood sugar events after gastric bypass, sponsor reports
LUCIDITY’s 55% figure combines two levels of hypoglycemia. It does not mean 55% fewer patients had a severe episode.
For some people who have had Roux-en-Y gastric bypass, repeated drops in blood sugar make an ordinary meal or a day away from home unpredictable. Amylyx reported results from a trial of avexitide, an investigational drug being studied for post-bariatric hypoglycemia.
LUCIDITY randomized 78 adults with this condition to avexitide or placebo. The blinded comparison lasted 16 weeks, and both groups received usual dietary management for the condition. The primary measure was how often blood sugar fell to a specified low level or an adjudicated event was severe enough to require another person’s help.
Amylyx reported estimated weekly rates of 0.55 combined events on avexitide and 1.24 on placebo, a 55% lower event rate. This is a difference in repeated events, not the percentage of people who had any low, and not the effect on severe events alone. The sponsor reported a 47% reduction for adjudicated severe events in a separate secondary analysis.
The sponsor described adverse events as generally mild or moderate, mainly gastrointestinal or injection-site symptoms. It reported no deaths or treatment-related serious adverse events during the blinded period. With 78 participants and 16 weeks of blinded follow-up, uncommon and long-term harms remain uncertain.
These are sponsor-reported conference results for a specific complication after one type of surgery. The finding is a reason to look for the full peer-reviewed analysis and regulatory evaluation, not to assume the evidence applies to other forms of hypoglycemia or that the investigational drug is approved.
Sources
Longevity & Healthspan
Higher Dietary Essential Amino Acid Intake Was Linked to Lower Mortality
A large observational analysis found a difference between intake groups. It did not show that increasing intake or taking supplements helps people live longer.
Essential amino acids are building blocks of proteins that the body must obtain from the diet. Rather than looking at one amino acid at a time, researchers examined patterns of intake across 161,420 people in two datasets: the UK Biobank and the U.S. National Health and Nutrition Examination Survey. They identified four intake groups, from low to very high, then compared mortality across the groups. During a median of 14.2 years of follow-up, 14,518 people died.
Compared with the low-intake group, the estimated hazard of death from any cause was 13% lower in the moderate group, 16% lower in the high group, and 13% lower in the very-high group. These are relative estimates, not differences in the share of people who died. The authors observed associations in the same direction for deaths from cardiovascular disease and cancer.
The highest intake group did not show a larger association than the high group. More importantly, the study did not assign participants to eat different diets, so it cannot isolate the effect of amino acids from the rest of what people ate or other differences between the groups.
A follow-up study would need to test whether changing intake improves outcomes rather than merely identifying which diets accompany better outcomes. The present analysis offers a reason to study the question further, not a new daily protein target or evidence that an amino acid supplement extends life.
Open this article on its own → Explore the related Living Magazine →
Markets & Strategy
Johnson & Johnson Agrees to Buy Ollin to Advance an Experimental Retinal Treatment
The proposed deal separates the acquisition price from funding for a phase 3 program. No treatment benefit is established by either commitment.
Johnson & Johnson said on November 16 that it signed a definitive agreement to acquire Ollin Biosciences, the developer of OLN324, an experimental treatment for retinal diseases including wet age-related macular degeneration and diabetic macular edema. The transaction is not complete. Johnson & Johnson expects it to close by year-end, subject to regulatory approvals and customary conditions.
The acquisition calls for $2.2 billion upfront at closing, plus up to approximately $1.125 billion in payments tied to regulatory and commercial milestones. That produces the roughly $3.3 billion headline figure, but the full amount is neither guaranteed nor already paid. In a separate arrangement contingent on the acquisition closing, Blackstone Life Sciences would provide $750 million to Johnson & Johnson over several years to fund phase 3 development. That is development funding, not a payment for Ollin, and should be tracked separately from the deal price.
What matters for patients is what the studies show. OLN324 is intended to act on two pathways involved in retinal disease. Johnson & Johnson says it might offer better control of fluid in the retina or allow longer intervals between treatments. Those are goals, not established benefits or evidence that the candidate outperforms current care.
The questions to watch are whether people maintain or improve their vision, how often they need treatment, and what harms emerge in a larger trial.